About Dr Fareed Ali
For more than 12 years, Dr. Fareed Ali has served as director of clinical research at the Canadian Centre for Advanced Eye Therapeutics (CCAET), the research division of the Ophthalmic Consultant Centre (OCC) in Ontario, Canada. As a clinical ophthalmologist at OCC, he specializes in the treatment of retinal disease and has introduced improved therapies now widely utilized by practitioners in the field. His advancement of the use of micropulse laser procedures to treat age-related macular degeneration is one such innovation; it allows for safer treatment of patients with this condition. In his research role at CCAET, Dr. Fareed Ali conducts clinical trials sponsored by biotechnology and multinational pharmaceutical companies like Regeneron, GlaxoSmithKline, and Novartis.
Prior to starting with OCC, Dr. Ali underwent an extensive 12-year period of continuous education and training, beginning with his premedical studies at the University of Manitoba. In 1992, he completed his MD at the University of Toronto Faculty of Medicine, and then began his internship at the Toronto Hospital. He then returned to the University of Toronto to serve a three-year ophthalmology residency, before accepting a retinal disease fellowship with Harvard Medical School. Moreover, Dr. Fareed Ali has been an ophthalmology Fellow of the Royal Canadian Surgeons of Canada since 1996.
Prior to starting with OCC, Dr. Ali underwent an extensive 12-year period of continuous education and training, beginning with his premedical studies at the University of Manitoba. In 1992, he completed his MD at the University of Toronto Faculty of Medicine, and then began his internship at the Toronto Hospital. He then returned to the University of Toronto to serve a three-year ophthalmology residency, before accepting a retinal disease fellowship with Harvard Medical School. Moreover, Dr. Fareed Ali has been an ophthalmology Fellow of the Royal Canadian Surgeons of Canada since 1996.